David C. Plough

St. Francis Medical Technologies, Inc. designs and develops equipment for orthopedic and neurological spine surgery. It also manufactures and markets spinal devices. The company was founded by Henry A. Klyce Jr., Ken Hsu, Charles J. Winslow, and James Zucherman 1997 and is headquartered in Sunnyvale, CA.

ROX Medical, Inc. manufactures medical ultrasonic scanning devices. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was founded by Rodney Brenneman and John Faul in 2004 and is headquartered in San Clemente, CA.

Medtronic Ablation Frontiers LLC provides technology solutions for cardiac therapy to cure heart arrhythmias focusing on a trial fibrillation. The firm focuses in the treatment of ablation therapy. The company was founded in 2004 and is headquartered in Carlsbad, CA.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Acclarent, Inc. engages in manufacturing, designing, and commercializing medical devices that address conditions affecting the ear, nose, and throat. Its products include balloon sinuplasty, eustachian tube dilation, airway dilation system, and ethmoid punch. The company was founded by Joshua Makower and John Y. Chang in June 2004 and is headquartered in Irvine, CA.

Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA.

Relievant Medsystems, Inc. develops treatment and technologies for chronic back pain. Its Intracept System solution is a minimally invasive procedure that uses radiofrequency energy delivered into the vertebral body of the spine to ablate the basivertebral nerve. Relievant Medsystems was founded by James C. Peacock, Jeffrey Charles Lotz, and Rex Peters in 2004 and is headquartered in Redwood City, CA.

VertiFlex, Inc. operates as a medical device company. It offers minimally invasive solutions for the treatment of lumbar spinal stenosis (LSS), which is the cause of spinal surgery in the elderly. The firm specializes in minimally invasive, motion preservation, spine and medical device. The company was founded by Moti Altarac in 2005 and is headquartered in San Clemente, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

VytronUS, Inc. develops imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias. The firm develops a catheter-based ablation platform based on low-intensity collimated ultrasound (LICU) which allows for precise non-contact energy delivery and producing high-resolution maps of cardiac anatomy. The company was founded by Hira V. Thapliyal in 2006 and is headquartered in Sunnyvale, CA.

Advanced Animal Diagnostics, Inc. develops integrated systems and solutions for the detection of animal diseases. The firm engages in the researching, developing and commercializing on-farm diagnostic tests, such as QScout MLD for early detection of subclinical mastitis in dairy cows. It also provides solutions for the diagnosis and treatment of veterinary health problems including mastitis and other animal diseases. The company was founded by Rodolfo Rodriguez and Victor M. Minton in July 2001 and is headquartered in Durham, NC.

Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Sensitech, Inc. provides cold chain solutions for monitoring temperature-sensitive and perishable products. Its products encompasses in software, dataloggers, logistics security, chemical and electronic indicator, strip chart recorders, ethylene absorption, facility monitoring, and accessories. The company was founded by Ernest M. Santin in 1990 and is headquartered in Beverly, MA.

Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts.

Micro Interventional Systems, Inc. designs and manufactures medical devices. It develops catheters for interventional neuroradiology. The company was founded in 1993 and is headquartered in Sunnyvale, CA.

Part of Johnson & Johnson, Atrionix, Inc. is a company that develops a proprietary, catheter-based system for the treatment of atrial fibrillation. The company is based in Palo Alto, CA. The company was founded by James C. Peacock. Atrionix was acquired by Cordis Corp. on December 27, 2000 for $62.80 million.

Part of Cordis Corp., Webster Laboratories, Inc. is a laboratory type distilling apparatus company. The company is based in Baldwin Park, CA. Webster Laboratories was acquired by Cordis Corp. on April 25, 1994 for $78.66 million.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Mid-Atlantic Venture Funds (Mid-Atlantic Venture Funds) is a venture capital firm founded in 1984 by Fred J. Beste. The firm is headquartered in Bethlehem, Pennsylvania.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

Visiogen, Inc. develops products for cataract and refractive patients. It offers synchrony dual-optic accommodating intraocular lens and pre-loaded injector, which provide distance, intermediate, and near vision to presbyopic cataract patients. The company was founded on March 19, 2001 and is headquartered in Abbott Park, IL.

Michigan Ross Zell Lurie Institute / Venture Capital/ (Zell Lurie Institute) is a venture capital subsidiary of Zell Lurie Institute for Entrepreneurial Studies Studies founded in 1997 by Samuel Zell, Ann Lurie and Robert H. Lurie. The firm is headquartered in Ann Arbor, Michigan.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

Ebb Therapeutics, Inc. develops medical devices for the treatment of insomnia. It engages in the development of regional cerebral thermal therapy (RCTT) device for use in insomnia and sleep disorders. The company was founded by Eric A. Nofzinger in 2008 and is headquartered in Pittsburgh, PA.

Woebot Labs, Inc. develops mental health chatbot. It serves people suffering from anxiety, depression and other serious mental health issues. The company was founded by Alison Darcy on July 7, 2017 and is headquartered in San Francisco, CA.

DocMatter, Inc. is a digital health company, which engages in the development of an online, peer-to-peer collaboration platform that streamlines knowledge access across a global network of healthcare professionals. The company was founded by Eric Applegate and is headquartered in San Francisco, CA.

Spectrawave, Inc. provides medical devices. The company is headquartered in Waltham, MA.

Faro Health, Inc. redefines how clinical protocols are developed by connecting all stakeholders in the clinical trials ecosystem through a single software platform. The company is based in La Jolla, CA. The platform provides a standardized library of clinical study activities and performance-related metadata, offering real-time actionable insights during protocol development. Faro brings transparency, trust, and predictability to protocol development by analyzing the impact of each study activity. This ensures that clinical protocols developed using Faro's platform are operationally efficient, answering crucial questions in the least burdensome way for patients, payors, and regulators. Faro Health was founded by Scott Matthew Chetham and Ross A. Jaffe, with Scott Matthew Chetham serving as the CEO since incorporation.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.